menu

Medical Industry Feature: Resistance in Vulvovaginal Candidiasis (VVC) - A Growing Problem

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
monistat

Resistance in Vulvovaginal Candidiasis (VVC) - A Growing Problem

Program Information
Recommended
Resistance in Vulvovaginal Candidiasis (VVC) - A Growing Problem
RestartResume
Drug resistance in VVC may impact your patients’ response to treatments. Learn about resistance causes, challenges and implications for VVC treatment.
  • Sponsored by

  • Overview

    Years ago only 5% of vaginal yeast infections were caused by non-albicans Candida. Today, an estimated 30% are caused by these species—and they’re becoming less responsive to fluconazole. This abridged version of Dr. Mark G. Marten's well-received conference presentation provides a useful overview of fluconazole resistance in VVC and covers such topics as:

    • Trends in drug resistance in VVC
    • How drug resistance happens in VVC
    • Dramatic increases in fluconazole dosages
    • Guidelines for treating non-albicans VVC
    • Special treatment considerations for pregnant and diabetic patients

     

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/6/19

    Get a Dose of ReachMD in Your Inbox
    and Practice Smarter Medicine

    Stay current with the best in medical education.